Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The diphtheria, tetanus, and pertussis vaccine (adsorbed) produced by the Butantan Foundation is a trivalent combination vaccine used for active immunization against diphtheria, tetanus, and pertussis. It contains purified diphtheria and tetanus toxoids along with inactivated whole-cell Bordetella pertussis bacteria, all adsorbed onto an aluminum hydroxide adjuvant to enhance immunogenicity. The vaccine induces the production of specific antitoxins that neutralize the toxins produced by Corynebacterium diphtheriae and Clostridium tetani, while the whole-cell pertussis component triggers a broad immune response against various bacterial antigens. This vaccine is a critical component of pediatric vaccination programs in Brazil, manufactured locally to ensure supply for the national health system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphtheria, tetanus and pertussis vaccine (adsorbed).